REDWOOD CITY, Calif. & BOSTON / Dec 31, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on December 31, 2024. One individual was hired by Adicet in December 2024 and granted new hire non-qualified stock options to purchase 9,000... Read More

Enrollment underway for patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) Company expects to share preliminary Phase 1 clinical data in the first half of 2025 REDWOOD CITY, Calif. & BOSTON / Dec 19, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today... Read More

Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization REDWOOD CITY, Calif. & BOSTON / Dec 18, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced... Read More

REDWOOD CITY, Calif. & BOSTON / Nov 29, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 29, 2024. One individual was hired by Adicet in November 2024 and granted new hire non-qualified stock options to purchase 6,000... Read More

First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials Preliminary Phase 1 clinical data expected in the first half of 2025 REDWOOD CITY, Calif. & BOSTON / Nov 18, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced... Read More

Enrollment underway for lupus nephritis (LN) patients Preliminary clinical data in LN anticipated in 1H25 Initiation of patient enrollment in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) expected in 1Q25; patient enrollment in anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) expected in 2H25 REDWOOD CITY, Calif.... Read More

Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases The company is pursuing ADI-001 in a basket study across six indications... Read More

ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis (LN) anticipated in 1H25 Strong balance sheet with $202.1 million in cash, cash equivalents and short-term investments as of September 30, 2024 REDWOOD CITY, Calif. & BOSTON / Nov 06, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company... Read More

REDWOOD CITY, Calif. & BOSTON / Nov 05, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.... Read More

REDWOOD CITY, Calif. & BOSTON / Nov 01, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November. Details of the events are as follows: Truist Securities BioPharma Symposium,... Read More

REDWOOD CITY, Calif. & BOSTON / Oct 31, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2024. Three individuals were hired by Adicet in October 2024. In the aggregate, Adicet granted new hires non-qualified stock... Read More

ADI-001 clinical development program now addresses six autoimmune diseases Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be initiated in the first quarter of 2025 Company plans to report initial clinical data from Phase 1 study in multiple autoimmune diseases in the first half of 2025 REDWOOD CITY, Calif. & BOSTON / Oct 16, 2024 / Business Wire / Adicet Bio, Inc.... Read More

REDWOOD CITY, Calif. & BOSTON / Sep 30, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on September 30, 2024. Four individuals were hired by Adicet in September 2024. In the aggregate, Adicet granted new hires non-qualified stock... Read More

REDWOOD CITY, Calif. & BOSTON / Sep 30, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, taking... Read More

Activated clinical sites for Phase 1 trial of ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) Enrollment open for patients with LN; enrollment in SLE, SSC, and AAV expected to open in the fourth quarter of 2024 REDWOOD CITY, Calif. & BOSTON / Sep 30, 2024 / Business Wire... Read More

Results highlight ADI-001's potential as a best-in-class allogeneic cell therapy for autoimmune disease Webcast featuring Dr. Blake Aftab with accompanying presentation available on Company website REDWOOD CITY, Calif. & BOSTON / Sep 19, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and... Read More

REDWOOD CITY, Calif. & BOSTON / Aug 30, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 30, 2024. Three individuals were hired by Adicet in August 2024. In the aggregate, Adicet granted new hires non-qualified stock options... Read More

REDWOOD CITY, Calif. & BOSTON / Aug 27, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference being held from September 9-11, 2024 in... Read More

REDWOOD CITY, Calif. & BOSTON / Aug 19, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. “We are pleased to welcome Dr. Klickstein to our Board of Directors,” said Chen Schor, President... Read More

ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV), following recent U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearances IND clearance for ADI-270 for the treatment of patients with relapsed/refractory renal cell... Read More

REDWOOD CITY, Calif. & BOSTON / Aug 01, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in two upcoming investor conferences in August. Details of the events are as follows: BTIG Virtual Biotechnology Conference, August... Read More

REDWOOD CITY, Calif. & BOSTON / Jul 31, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on July 31, 2024. Four individuals were hired by Adicet in July 2024. In the aggregate, Adicet granted new hires non-qualified stock options to... Read More

REDWOOD CITY, Calif. & BOSTON / Jul 08, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal... Read More

REDWOOD CITY, Calif. & BOSTON / Jun 28, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on June 28, 2024. Two individuals were hired by Adicet in June 2024. In the aggregate, Adicet granted new hires non-qualified stock options to... Read More

ADI-270 is the first gamma delta 1 CAR T candidate to enter clinical development for solid tumors Phase 1 clinical study to evaluate safety and anti-tumor activity of ADI-270 in relapsed/refractory RCC patients Phase 1 clinical study to be initiated in 2H 2024; preliminary clinical data expected in 1H 2025 REDWOOD CITY, Calif. & BOSTON / Jun 24, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage... Read More

REDWOOD CITY, Calif. & BOSTON / Jun 05, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus... Read More

REDWOOD CITY, Calif. & BOSTON / May 31, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on May 31, 2024. Two individuals were hired by Adicet in May 2024. In the aggregate, Adicet granted new hires non-qualified stock options to... Read More

REDWOOD CITY, Calif. & BOSTON / May 29, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 5-6, 2024 in New York.... Read More

On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting; on track to file investigational new drug (IND) in renal cell carcinoma in 2Q 2024 Strong balance sheet with $247.6 million in cash and cash equivalents as of March 31, 2024 REDWOOD CITY, Calif. & BOSTON / May 14,... Read More

REDWOOD CITY, Calif. & BOSTON / May 14, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024. Details of... Read More

REDWOOD CITY, Calif. & BOSTON / May 07, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Citizens JMP Life Sciences Conference being held from May 13-14, 2024... Read More

REDWOOD CITY, Calif. & BOSTON / Apr 30, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on April 30, 2024. One individual was hired by Adicet in April 2024 and granted new hire non-qualified stock options to purchase 7,800 shares... Read More

Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) application for ADI-270 in 2Q 2024 Preclinical data will be featured in oral presentation on May 10, 2024 REDWOOD CITY, Calif. & BOSTON / Apr 22, 2024 /... Read More

REDWOOD CITY, Calif. & BOSTON / Apr 08, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.... Read More

REDWOOD CITY, Calif. & BOSTON / Mar 28, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was hired by Adicet in March 2024 and granted new hire non-qualified stock options to purchase 99,400 shares... Read More

Expanded clinical pipeline into autoimmune diseases with U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Application (IND) for ADI-001; initiation of Phase 1 clinical trial in lupus nephritis expected in 2Q 2024 On track to file IND for ADI-270 in renal cell carcinoma in 2Q 2024 Extended projected cash runway into 2H 2026 REDWOOD CITY, Calif. & BOSTON / Mar 19, 2024 / Business Wire / Adicet Bio,... Read More

REDWOOD CITY, Calif. & BOSTON / Mar 11, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March... Read More

REDWOOD CITY, Calif. & BOSTON / Feb 29, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on February 29, 2024. One individual was hired by Adicet in February 2024 and granted new hire non-qualified stock options to purchase 7,000... Read More

REDWOOD CITY, Calif. & BOSTON / Feb 05, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference being held... Read More

REDWOOD CITY, Calif. & BOSTON / Jan 31, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on January 31, 2024. One individual was hired by Adicet in January 2024 and granted new hire non-qualified stock options to purchase 7,000... Read More

REDWOOD CITY, Calif. & BOSTON / Jan 25, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the closing of its previously announced underwritten public offering of 32,379,667 shares of its common stock, which includes 5,325,000 shares sold and issued upon the... Read More

REDWOOD CITY, Calif. & BOSTON / Jan 22, 2024 / Business Wire / Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten public offering of 27,054,667 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to... Read More

REDWOOD CITY, Calif. & BOSTON / Jan 22, 2024 / Business Wire / Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares... Read More

Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell... Read More

REDWOOD CITY, Calif. & BOSTON / Jan 03, 2024 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call... Read More

REDWOOD CITY, Calif. & BOSTON / Dec 29, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on December 29, 2023. One individual was hired by Adicet in December 2023 and granted new hire non-qualified stock options to purchase 84,000 shares of Adicet’s common... Read More

ADI-001 showed robust dose-dependent expansion and persistence in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL) Strong exposure and persistence profile further supports Adicet’s allogeneic chimeric antigen receptor (CAR) T platform potential as best-in-class Pharmacodynamic (PD) and pharmacokinetic (PK) analyses will be presented during poster presentation at ASH Annual Meeting on Sunday,... Read More

Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL) Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 study Prioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2024 REDWOOD CITY, Calif. & BOSTON / Nov 08, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a... Read More

REDWOOD CITY, Calif. & BOSTON / Nov 07, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London. Details of the event are as... Read More

REDWOOD CITY, Calif. & BOSTON / Nov 02, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65 th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023. Details of the poster... Read More

REDWOOD CITY, Calif. & BOSTON / Oct 31, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on October 31, 2023. One individual was hired by Adicet in October 2023 and granted new hire non-qualified stock options to purchase 5,000 shares of Adicet’s common... Read More

Preclinical study shows Adicet’s Allogeneic Gamma Delta T Cell Platform may be a Promising Approach for Prostate Cancer REDWOOD CITY, Calif. & BOSTON / Oct 04, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on... Read More

REDWOOD CITY, Calif. & BOSTON / Sep 29, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on September 29, 2023. Four individuals were hired by Adicet in September 2023. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 32,200... Read More

REDWOOD CITY, Calif. & BOSTON / Sep 27, 2023 / Business Wire / Adicet Bio, Inc. ( Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38 th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.... Read More

REDWOOD CITY, Calif. & BOSTON / Aug 31, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on August 31, 2023. Two individuals were hired by Adicet in August 2023. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 12,200 shares... Read More

Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application (IND) for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.5 million in cash and cash equivalents as of June... Read More

REDWOOD CITY, Calif. & BOSTON / Aug 02, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 43 rd Annual Growth Conference being held from August 7-10, 2023 in Boston.... Read More

REDWOOD CITY, Calif. & BOSTON / Jul 31, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on July 31, 2023. Four individuals were hired by Adicet in July 2023. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 73,400 shares of... Read More

REDWOOD CITY, Calif. & BOSTON / Jul 11, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Katie Peng to its Board of Directors. “We are delighted to welcome Katie to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “Her... Read More

REDWOOD CITY, Calif. & BOSTON / Jun 30, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on June 30, 2023. Seven individuals were hired by Adicet in June 2023. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 73,400 shares... Read More

ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T... Read More

REDWOOD CITY, Calif. & BOSTON / Jun 01, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York. Details of the event... Read More

REDWOOD CITY, Calif. & BOSTON / May 31, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on May 31, 2023. Three individuals were hired by Adicet in May 2023. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 34,800 shares of... Read More

ADI-270 includes Adicet’s proprietary armoring technology and enhancements designed for improved persistence and durability within a solid tumor microenvironment (TME) ADI-270 demonstrated potent anti-tumor activity in CD70+ cancers and improved resilience to clearance from host immune targeting REDWOOD CITY, Calif. & BOSTON / May 18, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology... Read More

REDWOOD CITY, Calif. & BOSTON / May 09, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 JMP Securities Life Sciences Conference being held from May 15-16, 2023 in New York. Details of the event are as... Read More

On track to report additional efficacy, durability and safety data and provide a regulatory update and plan for ADI-001 pivotal program in 2Q 2023 Strong balance sheet with $231.6 million in cash, cash equivalents and investments as of March 31, 2023 REDWOOD CITY, Calif. & BOSTON / May 09, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic... Read More

REDWOOD CITY, Calif. & BOSTON / Apr 28, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April 28, 2023. Seven individuals were hired by Adicet in April 2023. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 150,800... Read More

REDWOOD CITY, Calif. & BOSTON / Apr 13, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 20, 2023. Details of the event... Read More

REDWOOD CITY, Calif. & BOSTON / Mar 31, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March 31, 2023. Ten individuals were hired by Adicet in March 2023. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 237,400 shares... Read More

REDWOOD CITY, Calif. & BOSTON / Mar 15, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022. “In 2022, Adicet demonstrated strong execution in advancing our gamma delta T cell therapy... Read More

REDWOOD CITY, Calif. & BOSTON / Feb 28, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on February 28, 2023. Four individuals hired by Adicet in February 2023 received, in the aggregate, non-qualified stock options to purchase 105,400 shares of Adicet’s... Read More

REDWOOD CITY, Calif. & BOSTON / Feb 01, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference being held from February 8-9, 2023. Details of the event are as... Read More

REDWOOD CITY, Calif. & BOSTON / Jan 31, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January 31, 2023. Six individuals hired by Adicet in January 2023 received, in the aggregate, non-qualified stock options to purchase 72,800 shares of Adicet’s common... Read More

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on December 30, 2022. Two individuals hired by Adicet in December 2022 received, in the aggregate, non-qualified stock options to purchase 47,200 shares of Adicet’s common stock with an exercise price of $8.94 per share, the closing... Read More

ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL, as of December 5, 2022 data-cut date 100% ORR and CR rate in 5/5 anti-CD19 autologous chimeric antigen... Read More